Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1980 3
1981 3
1982 3
1983 4
1984 7
1985 1
1986 3
1987 1
1988 2
1990 2
1997 1
1998 1
2003 1
2006 1
2010 2
2011 3
2012 1
2013 4
2014 3
2015 5
2016 9
2017 3
2018 3
2019 2
2020 8
2021 10
2022 7
2023 12
2024 14
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Renal Cell Carcinoma: A Review.
Rose TL, Kim WY. Rose TL, et al. JAMA. 2024 Sep 24;332(12):1001-1010. doi: 10.1001/jama.2024.12848. JAMA. 2024. PMID: 39196544 Free PMC article. Review.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Rathmell WK, et al. Among authors: rose tl. J Clin Oncol. 2022 Sep 1;40(25):2957-2995. doi: 10.1200/JCO.22.00868. Epub 2022 Jun 21. J Clin Oncol. 2022. PMID: 35728020
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, Lee H, Gdowski AS, Raupp JD, Clark-Garvey S, Manocha U, Chafitz A, Sherman F, Stephens J, Rose TL, Milowsky MI, Wobker SE, Serody JS, Damrauer JS, Wong KK, Kim WY. Okato A, et al. Among authors: rose tl. J Clin Invest. 2024 Jan 16;134(2):e169241. doi: 10.1172/JCI169241. J Clin Invest. 2024. PMID: 38226620 Free PMC article.
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY. Rose TL, et al. Br J Cancer. 2021 Oct;125(9):1251-1260. doi: 10.1038/s41416-021-01488-6. Epub 2021 Jul 22. Br J Cancer. 2021. PMID: 34294892 Free PMC article.
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Beckabir W, Wobker SE, Damrauer JS, Midkiff B, De la Cruz G, Makarov V, Flick L, Woodcock MG, Grivas P, Bjurlin MA, Harrison MR, Vincent BG, Rose TL, Gupta S, Kim WY, Milowsky MI. Beckabir W, et al. Among authors: rose tl. Eur Urol. 2024 Mar;85(3):242-253. doi: 10.1016/j.eururo.2023.11.008. Epub 2023 Dec 12. Eur Urol. 2024. PMID: 38092611 Free PMC article.
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang HH, Wobker SE, Atassi G, Wilkinson AD, Fowler K, Flick LM, Damrauer JS, Harrison MR, McKinnon KP, Rose TL, Milowsky MI, Serody JS, Kim WY, Vincent BG. Beckabir W, et al. Among authors: rose tl. Nat Commun. 2024 May 24;15(1):4448. doi: 10.1038/s41467-024-48480-1. Nat Commun. 2024. PMID: 38789460 Free PMC article. Clinical Trial.
A multidisciplinary discussion of BladderPath.
St-Laurent MP, Sfakianos JP, Rose TL, Chung P, Kassouf W, Zlotta AR, Inman B, Black PC. St-Laurent MP, et al. Among authors: rose tl. Can Urol Assoc J. 2024 Mar;18(3):E91-E92. doi: 10.5489/cuaj.8525. Can Urol Assoc J. 2024. PMID: 38010224 Free PMC article. No abstract available.
Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features.
Wijetunga NA, Gessner KH, Kanchi K, Moore JA, Fleischmann Z, Jin DX, Frampton GM, Sturdivant M, Repka M, Sud S, Corcoran DL, Galsky MD, Milowsky MI, Wobker SE, Kim WY, Rose TL, Damrauer JS. Wijetunga NA, et al. Among authors: rose tl. Cancer Res Commun. 2024 Sep 1;4(9):2320-2334. doi: 10.1158/2767-9764.CRC-24-0352. Cancer Res Commun. 2024. PMID: 39113632 Free PMC article.
117 results